{
  "document_id": "HOUSE_OVERSIGHT_024917",
  "filename": "IMAGES-008-HOUSE_OVERSIGHT_024917.txt",
  "text": "COWEN\nCOLLABORATIVE INSIGHTS February 25, 2019\n\nADDENDUM\n\nStocks Mentioned In Important Disclosures\n\nTicker Company Name\n\nWEED Canopy Growth Corporation\nGWPH GW Pharmaceuticals Plc\nTLRY Tilray\n\nTPB Turning Point Brands\n\nImportant Disclosures and Information Relating to Cowen Washington Research Group\n\nCowen Washington Research Group produces commentaries on political, economic or market conditions. Commentaries produced by Cowen Washington Research Group are not\nintended as research reports as defined in FINRA Rule 2241 Research Analysts and Research Reports or FINRA Rule 2242 Debt Research Analysts and Debt Research Reports.\nSections of this report noted as authored by Cowen Washington Research Group have not been prepared, are not intended, and should not be interpreted as a research report or\ninvestment recommendation regarding securities of any company. Investors should not consider purchasing or selling securities based upon any information contained in sections of\nthe report denoted as authored by Cowen Washington Research Group.\n\nCowen Research Analyst Certification\n\nEach author of this research report hereby certifies that (i) the views expressed in the research report accurately reflect his or her personal views about any and all of the subject\nsecurities or issuers, and (ii) no part of his or her compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views expressed in this report.\n\nImportant Disclosures Relating to Cowen Research\n\nCowen and Company, LLC and or its affiliates make a market in the stock of GW Pharmaceuticals Plc, Tilray, Turning Point Brands and Canopy Growth Corporation securities.\n\nCowen and Company, LLC served as the placement agent in connection with Tilray's Series A preferred stock financing in February and March 2018.\n\nCowen and Company, LLC managed or co-managed a public offering of GW Pharmaceuticals Plc, Tilray, Turning Point Brands and Canopy Growth Corporation in the past 12 months.\n\nCowen and Company, LLC received compensation for investment banking services from GW Pharmaceuticals Plc, Tilray, Turning Point Brands and Canopy Growth Corporation in the\npast 12 months.\n\nGW Pharmaceuticals Plc, Tilray, Turning Point Brands and Canopy Growth Corporation is or has been in the past 12 months a client of Cowen and Company, LLC; Cowen and Company,\nLLC has provided or is providing investment banking services during the past 12 months.\n\nCowen and Company, LLC and/or its affiliates expect to receive, or intend to seek, compensation for investment banking services in the next 3 months from Tilray and Turning Point\nBrands.\n\nCowen and Company, LLC compensates research analysts for activities and services intended to benefit the firm's investor clients. Individual compensation determinations for research\nanalysts, including the author(s) of this report, are based on a variety of factors, including the overall profitability of the firm and the total revenue derived from all sources, including\nrevenues from investment banking, sales and trading or principal trading revenues. Cowen and Company, LLC does not compensate research analysts based on specific investment\nbanking transactions or specific sales and trading or principal trading revenues.\n\nThe Nielsen material contained in this report represent Nielsen's estimates and do not represents facts. Nielsen has neither reviewed nor approved this report and/or any of the\nstatements made herein.\n\nInformation contained in this report from The NPD Group, Inc. and its affiliates is the proprietary and confidential property of NPD and was made available for publication herein by\nway of limited license from NPD. Such NPD data may not be re-published in any manner, in whole or in part, without the express written consent of NPD.\n\nDisclaimer\n\nOur research reports and commentaries are simultaneously available to all clients are on our client website. Research reports and commentaries are for our clients only. Not all\nresearch reports and commentaries are disseminated, e-mailed or made available to third-party aggregators. Cowen and Company, LLC is not responsible for the redistribution\nof research or commentaries by third party aggregators. Selected research reports and commentaries are available in printed form in addition to an electronic form. All published\nresearch reports and commentaries can be obtained on the firmâ€™s client website, https://cowenlibrary .bluematrix.com/client/library jsp.\n\nThe information, opinions, estimates and forecasts are as of the date of this report and subject to change without prior notification. We seek to update our research and commentaries\nas appropriate, but various regulations may prevent us from doing so. Research reports and commentaries are published at irregular intervals as appropriate in the analyst's\njudgement.\n\nFurther information on subject securities may be obtained from our offices. This research report is published solely for information purposes, and is not to be construed as an offer\nto sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. Other than disclosures relating to Cowen and Company, LLC,\nthe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete statement or summary of the available data.\nAny opinions expressed herein are statements of our judgment on this date and are subject to change without notice. The opinions and recommendations herein do not take into\naccount individual client circumstances, objectives or needs and are not intended as recommendations of investment strategy. The recipients of this report must make their own\nindependent decisions regarding any securities subject to this research report. In some cases, securities and other financial instruments may be difficult to value or sell and reliable\ninformation about the value or risks related to the security or financial instrument may be difficult to obtain. To the extent that this report discusses any legal proceedings or issues,\nit has not been prepared to express or intended to express any legal conclusion, opinion or advice. Our salespeople, traders and other professionals may provide oral or written\nmarket commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed in our research. Our principal trading area and investing\nbusinesses may make investment decisions that are inconsistent with recommendations or views expressed in our research. Cowen and Company, LLC maintains physical, electronic\nand procedural information barriers to address the flow of information between and among departments within Cowen and Company, LLC in order to prevent and avoid conflicts of\ninterest with respect to analyst recommendations.\n\nFor important disclosures regarding the companies that are the subject of this research report, please contact Compliance Department, Cowen and Company, LLC, 599 Lexington\nAvenue, 20th Floor, New York, NY 10022. In addition, the same important disclosures, with the exception of the valuation methods and risks, are available on the Firm's disclosure\nwebsite at httos://cowen.bluematrix.com/sellside/Disclosures.action.\n\nCOWEN.COM 101\n\nHOUSE_OVERSIGHT_024917",
  "metadata": {
    "original_filename": "IMAGES-008-HOUSE_OVERSIGHT_024917.txt",
    "source_dataset": "huggingface:tensonaut/EPSTEIN_FILES_20K",
    "character_count": 7332,
    "word_count": 1094,
    "line_count": 87,
    "import_date": "2025-11-19T21:47:47.928981",
    "prefix": "IMAGES-008"
  }
}